Diagnostic Performance of Donor-Derived Plasma Cell-Free DNA Fraction for Antibody-Mediated Rejection in Post Renal Transplant Recipients: A Prospective Observational Study
Huanxi Zhang, Chunting Zheng, Xirui Li, Qian Fu, Jun Li, Qun Su, Liuhong Zeng, Liu Zu, Jiali Wang, Huiting Huang, Bowen Xu, Mingzhi Ye, Longshan Liu, Changxi Wang
Abstract
Objectives: To evaluate the diagnostic performance of donor-derived plasma cell-free DNA (cfDNA) in discriminating antibody-mediated rejection or de novo donor-specific antibodies (DSA) without histological lesions in kidney allograft recipients. Methods: In this prospective single center observational study, we enrolled kidney allograft recipients between November, 2016 and September, 2017 at the First Affiliated Hospital of Sun Yat-sen University. Kidney allograft recipients with antibody-mediated rejection (ABMR), de novo DSA but no histological lesions or negative DSA and stable renal function were included. The plasma cfDNA fraction was measured using a targeted, single nucleotide polymorphism(SNP)-based assay. Pathological diagnosis was made according to the 2015 Banff Kidney Rejection Classification. The area under the ROC curve (AUC-ROC) was determined using the bootstrapping method to estimate median and 95% confidence interval (95%CI). The sensitivity, specificity and Youden index, positive predictive value (PPV) and negative predictive value (NPV) were calculated for specific cfDNA fractions. Results: Totally 37 consecutive patients received kidney allografts, including 18 recipients in the ABMR group and 19 recipients in the stable allograft group (7 DSA-positive and 12 DSA-negative). All patients in the ABMR group were DSA positive and 7 patients in the stable group were DSA positive but had no pathologically proven ABMR. The median donor-derived plasma cfDNA fraction was 2.4% (Q1 1.52% -Q3 3.70%) in the ABMR group, and was significantly higher than that of the stable group (0.65%, Q1 0.57% -Q3 0.97%; P< 0.001), but comparable with that of the DSA-positive patients in the stable allograft group (P=0.074). The AUC-ROC of cfDNA was 0.90 (95%CI, 0.79-0.98). When a cfDNA threshold of 1% was chosen, it had a sensitivity of 88.9% and a specificity of 73.7%. The PPV was 76.2% and the NPV was 87.5%. Conclusions: Donor-derived plasma cfDNA fraction increased in kidney allograft recipients with ABMR. Detection of donor-derived plasma cfDNA fraction may contribute to the discrimination between ABMR and stable renal allograft function and may aid early recognition of earlier stage antibody-mediated injury.